- Conditions
- Septic Shock
- Interventions
- Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin
- Drug · Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,959 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 222
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anxiety Disorder
- Interventions
- Duloxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus
- Interventions
- Para-aminohippuric Acid, Angiotensin II, Norepinephrine
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Disease, End Stage Renal Disease
- Interventions
- Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Depression, Selective Serotonin Reuptake Inhibitor
- Interventions
- Not listed
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Major Depressive Disorder, Depression
- Interventions
- TC-5214, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
- Conditions
- Spinal Cord Injury
- Interventions
- Venlafaxine HCl, Placebo
- Drug · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Radiodermatitis
- Interventions
- Norepinephrine
- Drug
- Lead sponsor
- ProCertus BioPharm, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Orthostatic Hypotension, Idiopathic Parkinson Disease
- Interventions
- Droxidopa 100 MG [Northera]
- Drug
- Lead sponsor
- Alberto Espay, MD, MSc
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Depressive Disorder, Major
- Interventions
- JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
- Conditions
- Fibromyalgia
- Interventions
- AXS-14 (Esreboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
- Interventions
- Angiotensin II, Norepinephrine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Shock, Septic
- Interventions
- Vasopressin
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- ADHD
- Interventions
- Solriamfetol
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Jacksonville, Florida + 4 more
- Conditions
- Insomnia
- Interventions
- Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sepsis, Septic Shock
- Interventions
- vasopressin - early initiation, vasopressin - standard initiation
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Parkinson's Disease
- Interventions
- droxidopa, Placebo
- Drug
- Lead sponsor
- Colorado Springs Neurological Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Colorado Springs, Colorado
- Conditions
- Major Depressive Disorder
- Interventions
- LY03005
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Major Depressive Disorder
- Interventions
- AXS-05, Bupropion
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 40
- States / cities
- Bellflower, California • Lafayette, California • Oceanside, California + 34 more
- Conditions
- Joint Disease, Pain, Acute, Pain, Chronic
- Interventions
- Cymbalta, Placebo
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Depressive Disorder, Major
- Interventions
- 5 mg BI 1569912, 20 mg BI 1569912, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Garden Grove, California • Torrance, California • Miami, Florida + 7 more
- Conditions
- Anxiety Disorders, Depressive Disorders, Eating Disorders, Obsessive Compulsive Disorder
- Interventions
- Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sexual Dysfunction
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Dopamine Beta Hydroxylase (DBH) Deficiency
- Interventions
- droxidopa
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee